Using Streptavidin to Clear Radioactive Antibodies in Cancer Treatment
Author Information
Author(s): D. Marshall, R.B. Pedley, J.A. Boden, R. Boden, R.H.J. Begent
Primary Institution: Cancer Research Campaign Laboratories, Department of Clinical Oncology, Royal Free Hospital School of Medicine
Hypothesis
Does the degree of biotinylation of antibodies affect their clearance from the bloodstream when using streptavidin?
Conclusion
Streptavidin can significantly improve the tumor to blood ratio of radiolabeled antibodies, especially when the antibodies are highly biotinylated.
Supporting Evidence
- Using nine or 22 biotins per antibody molecule resulted in a 13- to 14-fold reduction in blood radioactivity.
- A 6.6-fold improvement in the tumor to blood ratio was achieved with increased biotinylation.
- Streptavidin clearance was compared to second antibody clearance, showing that second antibody was superior for blood clearance.
Takeaway
This study shows that adding more biotin to cancer-fighting antibodies helps them clear from the blood faster, making it easier to target tumors.
Methodology
The study involved injecting radiolabeled biotinylated antibodies into mice and measuring the clearance of these antibodies from the blood after administering streptavidin or a second antibody.
Potential Biases
Potential bias in the selection of antibody types and biotinylation methods could affect the results.
Limitations
The study primarily focused on a specific mouse model and may not fully represent human responses.
Participant Demographics
Nude mice bearing LS174T colon carcinoma xenografts.
Want to read the original?
Access the complete publication on the publisher's website